載入中
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
前收盤價
US$3.91
−US$0.01 · -0.26%
盤中時間採用ET。市場資料可能有所延遲。
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
日內區間
目前US$3.91
52週區間
目前US$3.91
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 14.79萬 USD | 8.26萬 USD | 1.55萬 USD | 1.51萬 USD | 1.56萬 USD |
| 毛利 | −14.79萬 USD | −8.26萬 USD | −1.55萬 USD | −1.51萬 USD | −1.56萬 USD |
| 研究與開發 | 2950.18萬 USD | 2718.81萬 USD | 2048.25萬 USD | 1028.74萬 USD | 252.56萬 USD |
| 銷售、一般及管理費用 | 808.26萬 USD | 615.46萬 USD | 1059.82萬 USD | 932.03萬 USD | 619.28萬 USD |
| 營業費用 | 3758.44萬 USD | 3334.27萬 USD | 3108.07萬 USD | 1960.77萬 USD | 871.52萬 USD |
| 利息收入 | 16.64萬 USD | 28.36萬 USD | 119.7萬 USD | 17.39萬 USD | 4017 USD |
| 利息支出 | 5.13萬 USD | — | — | 1244 USD | 10.02萬 USD |
| 折舊和攤銷 | 10.73萬 USD | 8.39萬 USD | 1.53萬 USD | 1.53萬 USD | 1.53萬 USD |
| 營業利益 | −3773.23萬 USD | −3334.27萬 USD | −3108.07萬 USD | −1960.77萬 USD | −871.52萬 USD |
| 淨利 | −3649.38萬 USD | −479.33萬 USD | −2711.44萬 USD | −3442.02萬 USD | −1726.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
